IP Australia handed a win Thursday to a company challenging a Bayer animal drug patent, but gave Bayer an additional two months to address its concerns about the patent application’s deficiencies.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au